The estimated Net Worth of Norbert W. & Inger A. Revoc... is at least 4.2 百万$ dollars as of 14 October 2020. Norbert Revoc owns over 95,500 units of Kronos Bio stock worth over 4,195,239$ and over the last 4 years Norbert sold KRON stock worth over 0$.
Norbert has made over 1 trades of the Kronos Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently Norbert bought 95,500 units of KRON stock worth 1,814,500$ on 14 October 2020.
The largest trade Norbert's ever made was buying 95,500 units of Kronos Bio stock on 14 October 2020 worth over 1,814,500$. On average, Norbert trades about 95,500 units every 0 days since 2020. As of 14 October 2020 Norbert still owns at least 4,370,496 units of Kronos Bio stock.
You can see the complete history of Norbert Revoc stock trades at the bottom of the page.
Norbert's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 300, SAN MATEO, CA, 94402.
Over the last 4 years, insiders at Kronos Bio have traded over 6,434,800$ worth of Kronos Bio stock and bought 7,151,111 units worth 30,320,233$ . The most active insiders traders include John C Martin、Norbert W Bischofberger、Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of 178,391$. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth 732,466$.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: